Dr. David Irwin of The University of Colorado and Dr Thies Schroeder look to overcome barriers to drug delivery in patients with pulmonary arterial hypertension with the development of their novel method for applying an endothelin blocking compound (Ambrisentan) in a reverse nanoshell emulsifier to the lungs via a nebulized mist. Oral and injectable drugs are the primary treatment options for patients with this disease. The barriers they pose to drug efficacy include delayed drug onset, unwanted drug removal via liver metabolism, and dependence on the patient's impaired circulatory capacity to reach the site of action. This method can be utilized in a mainstream commercial delivery platform such as a pressurized metered-dose inhaler and provide pulmonary hypertension patients with a stable and effective drug formulation in a much needed non-invasive convenient delivery platform.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/cu4310h_ncs.pdf